MOTS-c

Discovery and Origin

MOTS-c is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR) encoded within the 12S ribosomal RNA gene of mitochondrial DNA — not in the nuclear genome. It was identified in 2015 by Changhan David Lee, Pinchas Cohen, and colleagues at the USC Leonard Davis School of Gerontology, who were systematically searching mitochondrial reading frames for short open reading frames that might encode functional peptides. MOTS-c stands for "Mitochondrial Open reading frame of the Twelve S rRNA type-c" — an awkward but literal acronym for what it is.

MOTS-c belongs to a small but growing class of mitochondrial-derived peptides (MDPs), which also includes humanin (discovered 2003) and the six SHLP peptides. Together, these MDPs have reframed mitochondria from purely metabolic organelles into an unexpected source of endocrine-like signaling molecules.

Mechanism of Action

MOTS-c's principal biological activity is regulation of cellular and systemic metabolism through modulation of AMPK signaling and the folate-methionine cycle. Documented effects include:

• AMPK activation in skeletal muscle and other tissues, mimicking several of the metabolic effects of exercise.
• Improved insulin sensitivity and reduced diet-induced obesity in mouse models.
• Folate-methionine cycle modulation, which is thought to be one of the upstream mechanisms linking MOTS-c to AMPK.
• Nuclear translocation under metabolic stress — MOTS-c can enter the nucleus and regulate expression of adaptive metabolic genes, making it one of the few peptides known to move information directly from the mitochondrial to the nuclear genome.

Circulating MOTS-c levels decline with age in humans, and genetic variants in the MOTS-c-encoding region of mtDNA have been associated with metabolic phenotypes in Japanese cohorts — work that helped establish the peptide's functional relevance.

Preclinical and Early Clinical Evidence

Preclinical work on MOTS-c, largely from the Cohen lab and collaborators, has shown:

• Protection against diet-induced obesity and insulin resistance in mice.
• Improved exercise capacity in aged mice treated with MOTS-c.
• Cardioprotective effects in ischemia-reperfusion models.
• Bone-density and osteoblast-supportive effects in ovariectomized rodent models.

Human clinical data remains limited. A small number of observational studies have correlated circulating MOTS-c with metabolic health, exercise capacity, and aging phenotypes. Interventional trials of exogenous MOTS-c in humans are in early stages, with no Phase 3 readouts as of early 2026. MOTS-c is therefore best classified as an exciting mechanistic discovery with strong preclinical support but still-thin human efficacy data.

Practical Considerations

Research-chemical protocols using MOTS-c are a recent phenomenon and are extrapolated from rodent dosing rather than from human trial data. The peptide is not orally bioavailable in intact form; subcutaneous injection is the route used in research settings. Because the clinical evidence base is so thin, any specific protocol (commonly 5–10 mg per week, cycled) should be understood as speculative rather than clinically validated.

For a detailed overview of the mitochondrial-derived peptide class and its broader context in aging biology, see our MOTS-c peptide guide.

Regulatory and Safety Status

MOTS-c is not FDA- or EMA-approved for any indication. It is available only through research-chemical suppliers. Short-term safety signals from preclinical and early clinical work are favorable, but systematic human safety data simply does not exist at this time. Long-term effects of chronic exogenous administration — including any consequences of shifting circulating MDP levels outside physiological ranges — are unknown.

The Bottom Line

MOTS-c is one of the more scientifically interesting peptides to emerge in the last decade: it has a clear discovery story, a defined molecular mechanism, and a plausible biological rationale for its links to metabolism and aging. What it does not yet have is the human trial base that would justify confident therapeutic claims. For readers tracking aging biology, MOTS-c is worth following closely; for readers looking for a validated therapeutic, it is premature. See also humanin, its older mitochondrial-derived sibling, and our biological age overview for broader context.